Financials data is unavailable for this security.
View more
Year on year Taiko Pharmaceutical Co Ltd grew revenues 21.43% from 5.04bn to 6.12bn while net income improved from a loss of 4.89bn to a smaller loss of 3.61bn.
| Gross margin | 55.73% |
|---|---|
| Net profit margin | -37.15% |
| Operating margin | -38.98% |
| Return on assets | -16.12% |
|---|---|
| Return on equity | -26.20% |
| Return on investment | -19.68% |
More ▼
Cash flow in JPYView more
In 2023, Taiko Pharmaceutical Co Ltd increased its cash reserves by 87.49%, or 2.45bn. Cash Flow from Financing totalled 1.54bn or 25.15% of revenues. In addition the company used 307.00m for operations while cash from investing totalled 1.17bn.
| Cash flow per share | -39.50 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 160.66 |
|---|---|
| Tangible book value per share | 160.18 |
More ▼
Balance sheet in JPYView more
| Current ratio | 3.52 |
|---|---|
| Quick ratio | 2.83 |
| Total debt/total equity | 0.2765 |
|---|---|
| Total debt/total capital | 0.2166 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items increased 32.08%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.09 |
